Triflusal - A review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation

被引：34

作者：

Murdoch, David ^{[1
]}

Plosker, Greg L. ^{[1
]}

机构：

[1] Adis Int Ltd, Auckland 1311, New Zealand

来源：

DRUGS | 2006年 / 66卷 / 05期

关键词：

triflusal; atrial fibrillation; cerebral infarction; myocardial infarction; pharmacodynamics; pharmacoeconomics; pharmacokinetics; stroke; therapeutic use; thromboprophylaxis; tolerability;

D O I：

10.2165/00003495-200666050-00009

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Triflusal (Aflen((R)), Disgren((R)), Tecnosal((R)), Triflux((R))) is a novel platelet antiaggregant with structural similarities to salicylates, but which is not derived from aspirin. It has similar efficacy to aspirin in patients with cerebral or myocardial infarction, but has a reduced risk of haemorrhagic complications. In addition, triflusal plus moderate-intensity anticoagulation has demonstrated efficacy when used as thromboprophylaxis in atrial fibrillation. As such, triflusal has a role in the primary prevention of cerebrovascular events in atrial fibrillation, and for the secondary prevention of cerebral and myocardial infarction, primarily as an alternative to aspirin in patients for whom aspirin is unsuitable.

引用

页码：671 / 692

页数：22

共 79 条

[11] Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac):: prospective, randomized, co-operative trial [J].

Aramendi, JI ;

Mestres, CA ;

Martinez-León, J ;

Campos, V ;

Muñoz, G ;

Navas, C .

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2005, 27 (05) :854-860

[12]

Aramendi JL, 1998, J HEART VALVE DIS, V7, P610

[13] 4-trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potent inhibitors of nuclear factor κB activation [J].

Bayón, Y ;

Alonso, A ;

Crespo, MS .

BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (06) :1359-1366

[14]

Bertolucci A, 2002, NEW ENGL REV-MIDDLEB, V23, P23

[15]

Bescós LL, 1999, EUR HEART J SUPPL, V1, pF19

[16] ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-Segment elevation myocardial infarction - Summary article - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina) [J].

Braunwald, E ;

Antman, EM ;

Beasley, JW ;

Califf, RM ;

Cheitlin, MD ;

Hochman, JS ;

Jones, RH ;

Kereiakes, D ;

Kupersmith, J ;

Levin, TN ;

Pepine, CJ ;

Schaeffer, JW ;

Smith, EE ;

Steward, DE ;

Theroux, P ;

Gibbons, RJ ;

Alpert, JS ;

Faxon, DP ;

Fuster, V ;

Gregoratos, G ;

Hiratzka, LF ;

Jacobs, AK ;

Smith, SC .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (07) :1366-1374

[17] Effects of triflusal on arteriosclerosis progression assessed with high-resolution arterial ultrasound [J].

Cesarone, MR ;

Laurora, G ;

DeSanctis, MT ;

Incandela, L ;

Fugazza, L ;

Girardello, R ;

Poli, A ;

Peracino, L ;

Ambrosoli, L ;

Belcaro, G .

ANGIOLOGY, 1999, 50 (06) :455-463

[18] Randomized comparative trial of triflusal and aspirin following acute myocardial infarction [J].

Cruz-Fernández, JM ;

López-Bescós, L ;

García-Dorado, D ;

García-Aranda, VL ;

Cabadés, A ;

Martín-Jadraque, L ;

Velasco, JA ;

Castro-Beiras, A ;

Torres, F ;

Marfil, F ;

Navarro, E .

EUROPEAN HEART JOURNAL, 2000, 21 (06) :457-465

[19]

CRUZFERNANDEZ JM, 2001, EUROPEAN HEART J S1, V3, P23

[20]

CRUZFERNANDEZ JM, 1999, EUR HEART J SUPPL, V1, pF12

← 1 2 3 4 5 6 7 8 →